Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM ...

Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) • Company is ...

. Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM ...

• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically ...

Century Therapeutics (IPSC) has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

The chronic inflammatory myopathies are idiopathic, meaning they have no known cause. They are thought to be autoimmune disorders, in which the body's white blood cells (that normally fight ...

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.

A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic autoimmune disorders known for causing severe muscle weakness, fatigue ...

PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million ...

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM). According to GlobalData, Phase I drugs for Idiopathic Inflammatory ...